Bloomberg Businessweek Highlights Promise of Potential Drug VX-770
| 2 min read

A new CF treatment known as VX-770 will be a groundbreaking medicine if approved by the U.S. Food and Drug Administration, says Bloomberg Businessweek in this week's edition.

According to the article, VX-770 will be first pill designed to repair a genetic flaw based on the discovery of a mutation that causes a disease.

VX-770 is in the third and final stage of testing required for FDA approval. The drug was discovered in collaboration with the CF Foundation, which invested about $75 million in the project, and is being developed by Vertex Pharmaceuticals.

In a study of VX-770 released in February, the drug increased lung function by 10.5 percent over a year, reduced patients' need for antibiotics, and led to an average weight gain of seven pounds, the article notes. "We were euphoric," recalls Robert Beall, chief executive officer of the CF Foundation.

VX-770 is designed for a mutation, G551D, carried by about four percent of people with CF.

The CF gene was discovered in 1989. The news story describes the efforts of the CF Foundation, following the gene discovery, to encourage drugmakers to harness cutting-edge technology to develop new therapies to fight CF.

The magazine quotes Francis Collins, director of the National Institutes of Health and co-discoverer of the CF gene: “Discovering the genetic cause of a disease can lead you toward a therapy you never would have thought of otherwise."

Read the full Businessweek story on VX-770.

Share this article
Topics
About the CF Foundation | CFTR Modulators | Genetic Therapies
Recent news
Teens Advocate for the PASTEUR Act as Part of the CF Foundation’s 14th Annual Teen Advocacy Day
News | 4 min read
CF Foundation Awards $1.6 Million to Improve Detection of Lung Transplant Complication
News | 5 min read
CF Foundation Announces New National Advocacy Chairs
News | 5 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe